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Molecular monitoring of markers of antimalarial drug resistance offers an affordable alternative to the in 
vivo method for the detection of resistance, and has the potential to guide public health policy in a 
timely manner. However, the optimal way of analyzing and reporting these data, particularly those 
emanating from areas of moderate to high malaria transmission, has never been fully explored or 
agreed upon, given the potential of being confounded by coinfections. By using large number of real 
field samples, we quantified the difference between prevalence and frequency when reporting field data 
on antimalarial drug resistance obtained by direct counting of haplotypes. Polymerase chain reaction 
(PCR) and sequence specific oligonucleotide probing was used to generate point mutations which were 
used to construct haplotypes. Results indicate that frequency underestimates haplotypes present at 
low levels while also amplifying haplotypes present at high levels; prevalence on the other hand 
behaved in a vice versa manner. Both prevalence and frequency are therefore essential, as each may 
have relevance in different contexts in high malaria transmission settings. Frequency is essential to 
gauge the impact of intervention on antimalarial drug resistance while prevalence may be more relevant 
when the aim is to determine parasite clearance. 
 
Key words: Molecular markers, polymerase chain reaction (PCR) - sequence specific oligonucleotide probing 
(SSOP), prevalence, frequency. 
 
 
INTRODUCTION 
 
Malaria is one of the major public health challenges in 
areas of the world where the disease is endemic. Early 
diagnosis and prompt treatment of the disease with 
effective  drugs,  along  with  vector  control  are the main  
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strategies for its control in endemic areas, but the 
development and spread of drug resistance to the most 
commonly used anti-malarial drugs, has complicated this 
strategy (Olliaro, 2005). To provide essential information 
to the health authorities responsible for ensuring access 
to effective drugs by justification of alternative anti-
malarial drug policy, it is essential to quantify the level of 
drug resistance through regular monitoring of parasite 
resistance    (Hastings   et al.,   2007).   In  vivo    efficacy  
  
 
 
 
surveillance is a standard method for detection of 
resistance yet, the technique suffers logistical and 
financial constrains while its interpretation is confounded 
by factors such as reinfection, immunity, and 
pharmacokinetics (Uhleman et al., 2005).  
Surveillance designed to detect molecular markers of 
drug resistance offers rapid and affordable options to 
monitor parasite resistance in the field, and this approach 
has subsequently become an integral part for the 
evaluation of resistance to treatment (WHO, 2005; Plowe 
et al., 2007). In this approach, large numbers of infected 
blood samples can be collected and single nucleotide 
polymorphisms (SNPs)/mutations associated with drug 
resistance are rapidly screened and used to guide health 
policy decisions. For long time, there has been a call for 
optimization of methods for analyzing and reporting 
molecular markers of drug resistance, particularly in 
areas of intense malaria transmission characterized by 
multiple infections.  
An increasing number of molecular studies reporting 
the frequency of known resistance markers presents 
opportunities to assess the broader impact the study and 
reporting methodology may be having on the data being 
produced, notably reporting data with polyclonal 
infections (Djimde et al., 2001; Kublin et al., 2002). An 
account of problems associated with analysis of human 
blood samples from areas of moderate to high malaria 
transmission is given elsewhere (Hastings et al., 2010). 
Blood samples from these areas are often infected with 
multiple genetically distinct malaria clones and the 
number of co-infecting clones is known as multiplicity of 
infection (MOI). Samples for which MOI>1 and contains 
both wild type (sensitive) and mutant (resistant) 
genotypes, present an exceeding complication to 
determine the proportions of sensitive and resistant 
genotypes (Hastings et al., 2010). Furthermore, by using 
most of the available genotyping methods including 
polymerase chain reaction and restriction fragment length 
polymorphism (PCR-RFLP), it is also either difficult or 
completely impossible to assign specifically each of the 
various SNPs into specific parasites contained in a single 
patient blood sample, complicating the whole exercise of 
true haplotype construction from SNPs.  
Haplotypes are combinations of SNP that are in the 
same gene in the same parasite, as distinct from 
associations of point mutations that co-occur because 
there is a mixture of parasites of different genotypes 
within a single infection (Pearce et al., 2003). 
Consequently, haplotypes are biologically meaningful, 
since they determine the resistance properties of 
parasites that are exposed to drugs at the time of 
treatment (Pearce et al., 2003). For example, the genetic 
determinants of pyrimethamine and sulphadoxine 
resistance are point mutations at codons 16, 50, 51, 59, 
108, 164 and 436, 437, 540, 581, 613 of the dihydrofolate 
reductase-dhfr (Cowman et al., 1998) and 
dihydropteroate   synthase-dhps    (Brooks   et  al.,  1994)  
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genes, respectively and a mixed infection containing both 
51I+108N and 59R+108N double-mutant haplotypes is 
less resistant to pyrimethamine than an infection 
containing the triple-mutant 51I +59R+108N haplotype, 
despite all three mutations being present in either case. It 
is therefore advisable to measure the frequency of 
haplotypes rather than the prevalence of each point 
mutation separately, because haplotypes are the 
determinants of resistance levels.  
In this study, a high throughput sequence-specific 
oligonucleotide probe-based approach described by 
Pearce et al. (2003) was used to generate genotypic 
data. In this method, relative abundance of a given 
parasite genotype were inferred from intensity of probe 
signal such that the greater the intensity the greater the 
parasite population and vice versa, allowing for reliable 
assignment of SNPs to alternative genotypes and 
haplotype construction. 
As the number of molecular studies, reporting the 
frequency/prevalence of known resistance markers 
continues to mount,  researchers have started to realize 
the need to assess the broader impact that reporting 
conventions and study methodology may be having on 
the data being produced (Pearce et al., 2003; Hastings et 
al., 2010; Sridaran et al., 2010). While there is general 
consensus that, analysis and interpretation of samples 
from areas of moderate to high malaria transmission 
present difficulties because of genetic ambiguity resulting 
from high MOI (MOI>1), there is a varying opinion on the 
expression of the data into either frequency or prevalence 
due to overestimation or underestimation of the rare 
genotypes (Pearce et al., 2003; Hastings et al., 2010; 
Sridaran et al., 2010).  
A number of studies conducted in areas of moderate to 
high malaria transmission have raised concern about the 
implication that the use of prevalence and frequency of 
molecular markers of drug resistance might have when 
used as a tool for the provision of  information to guide 
policy (Pearce et al., 2003; Hastings et al., 2010).  
Hasting et al. (2010) defined prevalence as the 
proportion of human blood samples where the marker is 
present, implying that one or more clones in the sample 
carry the marker. He also defined frequency as the 
proportion of individual malaria clones that carries the 
marker. Prevalence requires accounting for all SNPs 
irrespective of their numbers. In an attempt to achieve 
consistent and comparable quality data on which rational 
decision to guide policy can be based, Hastings et al. 
(2010) wrote and updated a MalHaploFreq software, 
incorporating an aspect of maximum likelihood (ML) 
estimation of SNPs and haplotype frequencies, assuming 
that all clones are detectable and the appropriate 
genotyping sensitivity limit (GSL) to avoid 
misclassification in samples with MOI>1 from areas of 
moderate to high malaria transmission. As this awaits 
adoption by researchers, it may be important to quantify 
the  difference  between reporting field studies in terms of 
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prevalence and frequency emanating from direct count of 
SNPs or haplotypes, as until presently, this seems the 
predominant practice (Pearce et al., 2003; Roper et al., 
2003; Pearce et al., 2009; Malisa et al., 2010).  
This study reports a comparative analysis of 
prevalence and frequency of dhfr and dhps haplotypes in 
a large scale field samples from high malaria 
transmission area in south eastern Tanzania.  
 
 
MATERIALS AND METHODS 
 
Study area, subjects and samples 
 
Cross sectional community surveys were conducted during July, 
August and September of 2000 and 2006 in three rural districts of 
south-eastern Tanzania, Rufiji (Population = 170,000), Kilombero 
(Population = 220,000) and Ulanga (Population = 160,000). The 
three districts were well matched in terms of predicted intensity and 
duration of malaria transmission and risk (MARA), relative access 
and overall utilization of health services (based on surveys), usage 
of insecticide treated nets (ITNs) and relative proportion of urban 
peri-urban, rural population.  
The surveys were part of large combination therapy pilot 
implementation programme in Tanzania, the interdisciplinary 
monitoring programme for antimalarial combination therapy 
(IMPACT-TZ). Impact-Tanzania is a multiyear implementation 
research evaluation that rests on a collaborative platform 
incorporating the United States Center for Disease Control and 
Prevention (CDC), the Ifakara Health Institute, London School of 
Hygiene and Tropical Medicine, and the Ministry of Health and 
Social Welfare including its National Malaria Control Programme, 
the Tanzania Essential Health Interventions Project and the Council 
Health Management Teams of Rufiji, Kilombero and Ulanga 
Districts. Impact-Tanzania is primarily supported by funding from 
the United States Agency for International Development, CDC and 
Welcome trust.  
For the purpose of the study, Kilombero and Ulanga (KU) 
Districts were treated as a single district because population 
movement between these two districts is high and the study 
population spans the border region. Plasmodium falciparum malaria 
transmission in the study area is intense (with an estimated 
entomological inoculation rate of 367 infectious bites per person per 
year) (Hay et al., 2001) and perennial with some seasonal 
fluctuation.  
A total of 14,900 adults and children from the randomly selected 
households participated in the study. A finger-prick blood sample 
for blood slide and filter paper (3 MM; Whatman International Ltd., 
Maidstone, United Kingdom) bloodspot were collected from each 
individual in the household. The filter paper bloodspots were air-
dried and stored at room temperature in self-sealing plastic bags 
with dessicant.  All blood slide samples were screened by light 
microscopy for P. falciparum parasites. Bloodspots from 
microscopically positive subjects were selected for molecular 
genotyping. 
 
 
Ethics  
 
Scientific and ethical clearance was obtained from the Medical 
Research Council of the National Institute for Medical Research in 
Tanzania, the Centers for Disease Control and Prevention, USA, 
and the London School of Hygiene and Tropical Medicine. Written 
informed consent was obtained from all individuals or their 
guardians before collection of samples. 
 
 
 
 
DNA extraction 
 
The DNA was extracted from bloodspots dried on filter papers. A 
section of the dried blood spot filter paper was excised using a 
sterile blade or scissors, and soaked in a 1 ml, 0.5% saponin-1x 
phosphate buffered saline (PBS). The section of filter paper was 
then washed twice in 1 ml of 1x PBS and finally, was boiled for 8 
min in 100 μl PCR quality water with 50 μl 20% chelex suspension 
(pH 9.5). 
 
 
PCR amplification 
 
Nested PCR was used to amplify a 594 base pair (bp) fragment of 
dhfr and a 711 bp fragment of dhps each containing the sequence 
where mutations are found. Primer sequences and PCR reaction 
conditions were previously described in the study of Pearce et al. 
(2003). PCR was performed in 96 well plates with 25 μl PCR 
reaction volumes containing final concentrations of 0.25 μM each 
oligonucleotide primers, 2 mM MgCl2, 250 μM each 
deoxyribonucleotide triphosphate (dNTPs), and 1x Taq polymerase. 
One microliter (1 μl) of DNA template was used in the outer 
(primary) PCR reaction mixture for dhfr and dhps amplifications. For 
the inner (secondary) dhps reactions 1 μl of the outer PCR product 
was used. The outer dhfr PCR products were diluted three fold 
before 1 μl was introduced into the inner PCR reaction mixtures.  
 
 
Molecular genotyping of point mutations by sequence specific 
oligonucleotide probing (SSOP) 
 
The amplified PCR products were screened for dhfr and dhps 
sequence variants at 10 loci where SNPs associated with SP drug 
resistance are known to occur. The sequence changes (and the 
amino acid substitutions they code for) are summarized in Table 1.  
PCR products were spotted in a 12 by 8-grid and cross linked 
onto nylon membranes and probed for sequence polymorphisms by 
hybridization to specific oligonucleotide probes described previously 
in the study of Pearce et al. (2003).  For analysis of samples 
collected in 2000, the visualization of hybridized digoxygenin 
labeled probes on membranes was performed by the alkaline 
phosphatase-catalysed breakdown of the CSPD substrate (Roche 
Boehringer Mannheim, Mannheim, Germany) and visualized by 
exposure on Hyperfilm-ECL (Amersham Pharmacia Biotech, Little 
Chalfont, Buckinghamshire, United Kingdom), according to 
Boehringer Mannheim recommendations and previously described 
in the study of Conway et al. (1999).  
For analysis of samples collected in 2001 and 2002, the probed 
blots were visualized using ECF substrate and detection using a 
phosphoimager (STORM®). Inspection of autoradiographic films 
was carried out by light box illumination, while the phophoimager 
output was recorded through viewing of digitally-captured images of 
chemifluorescent signal. The change in the method by which probe 
hybridization signal was visualized did not affect the results in any 
way since the probes and hybridization conditions were unchanged. 
The stringency and specificity of the hybridization process was 
confirmed by inspection of a series of 4 controls with a known 
single genotype variant sequence. All blots with non-specifically 
bound probes were stripped and re-probed. A SNP was considered 
to be present in the PCR product when the intensity of signal was 
higher than that of the background. The blots were scored 
independently by two people. 
 
 
Estimation of haplotype frequency 
 
Haplotype frequency is defined as the proportion of individual 
malaria  clones  that  carries a particular haplotype. In the haplotype  
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Table 1. The nucleotide and amino acid substitutions at dhfr and dhps genes screened for by PCR-SSOP. 
 
Codon 
dhfr 
50 51 59 108 164 
Wild type Cys (C), TGT Asn (N), AAT, AAC Cys (C), TGT Ser (S),  AGC Ile (I), ATA 
Mutant Arg (R), CGT Ile (I), ATT Arg (R), CGT Asn (N), AAC, Thr (T), ACC Leu (L), TTA 
      
dhps 
Codon 436 437 540 581 613 
Wild type Ser (S), TCT Ala (A), GCT Lys (K), AAA Ala (A), GCG Ala  (A), GCC 
Mutant 
Phe (F), TTT, Ala (A), 
GCT, Cys (C), TGT 
Gly (G), GGT Glu (E), GAA Gly (G), GGG 
Ser (S), TCC, Thr 
(T), ACC 
 
 
 
frequency analysis, the aim was to establish the relative abundance 
of different point mutation haplotypes at dhfr and dhps. Since blood 
stage P. falciparum is haploid, this is very straightforward when an 
infection consists of a single genotype because only one form of 
sequence at every SNP locus is seen.  
When infections are composed of multiple genotypes a mixture of 
different sequence variants occurs making the inference of point 
mutation haplotypes within that infection more difficult. The 
presence, absence, and relative abundance of hybridization signal 
for every probe were recorded at each locus. A sample was 
considered to have a single haplotype when only one sequence 
variant was found at each locus. Blood samples were categorized 
as having a single, a majority, or a mixture of sequence at each 
SNP locus.  
Majority and mixed genotype infections were differentiated 
according to the relative intensity of signal. If the hybridization 
signal of the minority sequence was greater than half the intensity 
of the majority then an infection was classified as mixed. To 
determine the relative abundance of different point mutation 
haplotypes in the parasite population, only one haplotype was 
counted from each infection and those mixed infections where 
haplotypes could not be resolved were omitted from the calculation 
of haplotype frequencies. Hence, frequency data is based upon a 
subset of isolates which were either unmixed or had a 
predominating majority haplotype. Therefore, haplotype frequency 
was calculated as the ratio of allelic haplotypes among those 
infections where a single or majority haplotype was detected at the 
resistance locus. 
 
 
Estimation of haplotype prevalence 
 
Prevalence is defined as the proportion of human blood samples 
where the haplotype is present, implying that one or more clones in 
the sample carry the marker. In this analysis, the aim was to 
account for every point mutation haplotype. As for the frequency 
estimation, when only one sequence variant was found at each 
locus, the sample was considered to have a single haplotype and 
its estimation was straightforward.  
However, when infections are composed of multiple genotypes a 
mixture of different sequence variants occurs necessitating the 
need to disentangle individual point mutation haplotypes. This was 
achieved by listing all point mutation haplotypes present in each 
sample irrespective of whether they were of equal, minority or 
majority parasite population. Since the higher the number of 
constituent point mutations in a given haplotype, the more complex 
is the haplotype estimation, dhps haplotype prevalence was 
relatively easier to estimate than dhfr. 
Unlinked (selectively neutral) microsatellite loci analysis 
 
To examine the extent of the underlying rate of mixed infections 
and monitor transmission intensity in the study area, unlinked 
microsatellite markers (Poly A, Pfpk2 and TA109) were genotyped 
in a subset of samples; 180 samples from each of  Rufiji and KU  
populations, respectively in 2000, and an equal samples from each 
of the two populations in 2006. A semi-nested PCR was used to 
amplify microsatellites in 11.0 l reaction volumes. The 1° reaction 
composed of 1  template DNA, 1x thermo buffer, and 3.0 mmol/L 
Mg2+, 0.75 pmol/L of each primer and 1 unit of Taq polymerase. 
The cycling conditions were: 2 min at 94°C; and then 25 repeated 
cycles of 30 s at 94°C; 30 s at 42°C; 30 s at 40°C; and 40 s at 
65°C; followed by 2 min at 65°C.  
In the second round of PCR, a third fluorescent labeled primer 
(Applied Biosystems, Warrington, Cheshire UK) was incorporated 
and the final PCR reaction volume (11.0 l) consisted of 1x thermo 
buffer, 2.5 mmol/L Mg2+ , 2 pmol/L primer, 1 unit of Taq polymerase 
and 1 l of the outer (1°) PCR products. The cycling conditions 
were:  2 min at 94°C; and then 25 repeated cycles of 20 s at 94°C; 
20 s at 45°C; and 30 s at 65°C; followed by 2 min at 65°C. 
Semi nested PCR products were diluted at 1:100 ratio and run 
with LIZ – 500 size standards on an Abi 3730 genetic analyser 
(Applied Biosystems, Warrington, and Cheshire, UK). Fragments 
were sized using the Gene Mapper software (Applied Biosystems, 
Warrington, and Cheshire, UK). Multiplicity of infection for each 
sample was recorded by counting the number of peaks, each 
representing clonally different parasite (haploid nature of blood 
stages of P. falciparum). 
 
 
Statistical analysis 
 
Statistical comparison of allele prevalences and frequencies at dhfr 
and dhps was carried out using chi-squared analysis in STATA 
version 9.2 (Stata, 2002).  
 
 
RESULTS 
 
A total of 14,900 asymptomatic persons were sampled 
and 3,294 found infected with P. falciparum.  DNA was 
extracted from all P. falciparum positive samples and 
PCR amplification of dhfr and dhps performed, giving an 
average amplification success of 60% for both genes 
(Table 2).  The  amplified  products  were screened for all  
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Table 2. PCR outcome for the 2000 and 2006 house hold survey samples collected from two rural districts, Rufiji 
and KU in Tanzania. 
 
Parameter Rufiji  KU 
Year 2000 2006  2000 2006 
Survey population 2844 4267  3289 4500 
P. falciparum positive 778 916  955 645 
PCR amplified dhfr 549 683  404 294 
PCR amplified dhps 521 703  444 323 
Single or majority dhfr 455 616  376 275 
Single or majority dhps 417 588  365 275 
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Figure 1. MOI distribution in 2002 and 2006 isolates from Rufiji and KU populations determined by 
genotyping of three neutral microsatellites markers (Poly A, Pfpk2 and TA109). A = KU, B = Rufiji. 
 
 
 
the variant sequences described in Table 1. Out of the 
1,930 isolates which amplified successfully for dhfr, 89% 
were single or majority genotype infections. Of the 1,991 
samples which amplified successfully for dhps, 83% were 
single or majority genotype with known haplotypes. In 
reporting frequency, allelic haplotypes, the conformations 
of point mutations in dhfr and dhps were recorded only 
from single and majority genotype infections, while in the 
case of prevalence, all genotype infections were recorded 
irrespective of whether they represent minority or majority 
parasite population.  
The number of distinct P. falciparum genotypes 
detectable per sample is defined as the ‘multiplicity of 
infection’ (MOI). Since analysis of human blood samples 
from areas of moderate to high malaria transmission is 
complicated by MOI, it was necessary for this study to 
determine the underlying MOI in the study area at the 
time of sampling. Figure 1 shows estimation of MOI from 
the two sites, Rufiji and KU in years 2000 and 2006.  
In the year 2000, isolates from both Rufiji and KU 
districts had remarkably similar distribution of MOI 
(Figure 1). The most common MOI was 3 in both districts,  
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Figure 2. Comparison of dhfr haplotype prevalence and frequency in two populations of Rufiji and KU. A = prevalence,  
B = frequency. 
 
 
 
and an estimated 60 (33%) of 180 patients screened from 
each of Rufiji and KU were found to be coinfected with 3 
genetically distinct P. falciparum parasites. However, in 
2006, a trend towards reduction of malaria transmission 
was observed which was associated with the decrease of 
the most common MOI from 3 in both populations to 2 in 
Rufiji and 1 in KU. Generally, MOI analysis confirmed 
high malaria transmission in the populations with MOI 
ranging from 1 to 9 in both surveys.  
The point mutations found in the study area were N51I, 
C59R and S108N for the dhfr and S436A, S436F, 
S436C, A437G, and K540E for the dhps gene. While all 
the three dhfr point mutations were common and 
widespread, two of the dhps mutations, S436F and 
S436C, were very rare and the rest three mutations, 
S436A, A437G, and K540E, were common and 
widespread. The three dhfr mutations identified in this 
study were present in seven haplotypic conformation; 
CNCS, CNRN, CICN and CIRN, which were common 
and  widespread  and  CNCN,  CNRS  and  CICS,   which 
were extremely rare and occurred in a very low 
proportion. Likewise, for the dhps gene, the observed five 
point mutations were present in four common and 
widespread haplotypic conformations; SAKAA, AAKAA, 
SGEAA, SGKAA and five rare and low frequency 
haplotypes; SAEAA, CAKAA, FAKAA, AAEAA, and 
FAEAA. Detailed account of haplotype changes with time 
are described elsewhere (Malisa et al., 2010). 
Comparison between prevalence and frequency of dhfr 
and dhps haplotypes in the two study sites revealed a 
remarkably similar progression; indicating that the highly 
resistant haplotypes (CIRN and SGEAA) were increasing 
with time displacing the wild type haplotypes (CNCS, 
SAKAA) while the moderately resistant haplotypes 
(CNCN, CNRN, CICN and AAKAA) displayed almost a 
constant frequency or prevalence (Figures 2 and 3). The 
observed progression of dhfr and dhps haplotype 
prevalence and frequency is consistent with drug use 
history in Tanzania.  Sampling in 2000 was done one 
year  prior  to  policy  change  from CQ first line to SP first 
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Figure 3. Comparison of dhps haplotype prevalence and frequency in two populations of Rufiji and KU. A = 
prevalence, B = frequency. 
 
 
 
 line in 2001 (17 years of SP use as second line 
treatment) while sampling in 2006 took place after 5 
years of SP use as first line treatment, and thus it is 
plausible that the increased SP drug pressure resulting 
from its widespread use as national first line antimalarial 
drug could be attributed to the observed rise of resistant 
dhfr and dhps haplotypes in 2006.  
Our analysis has found a striking contrasting behaviour 
when comparing frequency with prevalence among the 
wild type (sensitive), the moderately resistant and the 
highly resistant dhfr and dhps haplotypes. While the 
frequencies were greater than prevalencies in the wild 
type and the highly resistant haplotypes (except the 
SGEAA in 2000 which behaved like the moderately 
resistant haplotypes), the moderately resistant 
haplotypes displayed an opposite relationship, showing 
prevalences which were greater than frequencies (Tables 
1 and 2).  
A closer comparison between haplotype prevalence 
and frequency revealed interesting differences between 
the  two  mutation  quantification methods (Table 3). Most 
striking differences were observed in wild type haplotypes 
and the highly resistant haplotypes in both the dhfr and 
dhps genes. The prevalence of the dhps wild type 
haplotype, the SAKAA in 2000 was 56 and 52% in Rufiji 
and KU while its frequency was 71 and 68% in Rufiji and 
KU, respectively; this difference was statistically 
significant (p≤0.0001). By contrast, in 2006, the 
prevalence and frequency of the wild type dhps haplotype 
(SAKAA) were remarkably closely similar, with 
prevalence of 32 and 28% in Rufiji and KU and frequency 
of 29 and 20% in Rufiji and KU, respectively this 
difference was not statistically significant (p≥0.05). 
For the highly resistant dhps haplotype (SGEAA), its 
prevalence in 2000 was 12 and 15% in Rufiji and KU, 
respectively while its frequency was 8 and 12% in Rufiji 
and KU, respectively this difference was statistically 
insignificant (p≥0.05). In 2006 its prevalence was 47.8% 
and 53.0% in Rufiji and KU, respectively while its 
frequency was 63.3 and 72.1% in Rufiji and KU, 
respectively, this difference was statistically significant 
(p≤0.0001). 
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Table 3. Comparison of dhfr and dhps haplotype prevalence and frequency in Rufiji and KU for the 2000 and 2006 isolates. 
 
Population Haplotype 
Year  
2000  2006 
Prevalence Frequency P value (95% CI)  Prevalence Frequency P value (95% CI) 
Rufiji 
SAKAA* 55.8 71.1 0.0001  31.9 29.1 0.435 
SGEAA 12.3 8.1 0.231  47.8 63.3 0.0001 
CNCS* 22.6 35.2 0.0001  7.1 3.6 0.189 
CIRN 23.4 37.4 0.0001  57.8 74.3 0.0001 
         
KU 
SAKAA* 51.8 67.7 0.0001  28.4 20.7 0.05 
SGEAA 14.6 12.1 0.402  53.0 72.1 0.0001 
CNCS* 28.5 51.2 0.0001  10.3 5.5 0.265 
CIRN 18.7 28.0 0.01  57.1 74.9 0.0001 
 
*Wild type haplotype.  
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Figure 4. Comparison of the prevalence and frequency of triple mutant dhfr  (CIRN) parasites in the two 
districts, Rufiji and KU.  
 
 
 
Comparison of prevalence and frequency of the wild type 
dhfr haplotype (CNCS) revealed significant differences in 
2000 but insignificant differences in 2006 isolates in the 
two study sites. In 2000, its prevalence was 22.6 and 
28.5% in Rufiji and KU, respectively while its frequency 
was 35.2 and 51.2% in Rufiji and KU, respectively; this 
difference was statistically significant (p≤0.0001). 
However, in 2006, its prevalence was 7.1 and 10.3% in 
Rufiji and KU, respectively while its frequency was 3.6 
and 5.5% in Rufiji and KU, respectively, this difference 
was not statistically significant (p≥0.05). 
Comparison of prevalence and frequency of the highly 
resistant dhfr haplotype (CIRN) revealed significant 
differences in both 2000 and 2006 isolates in the two 
study sites (Figure 4). In 2000, its prevalence was 23.4 
and 18.7% in Rufiji and KU, respectively while its 
frequency was 37.4 and 28.0% in Rufiji and KU, 
respectively, this difference was statistically significant 
(p≤0.001). Similarly, in 2006, its prevalence was 57.8 and 
57.1% in Rufiji and KU, respectively while its frequency 
was 74.3 and 74.9% in Rufiji and KU, respectively; this 
difference was statistically significant (p≤0.0001). 
Prevalence and frequency comparison of the triple 
mutant dhfr CIRN and the double mutant dhps SGEAA 
haplotypes, which have the greatest significance for SP 
efficacy, are shown in Figures 4 and 5, respectively. As 
described previously, the CIRN haplotype maintained 
similar relationship between prevalence and frequency, 
with frequencies being greater than prevalences at the 
two sampling points of 2000 and 2006 (Figure 4). 
However, the relationship was different for the SGEAA 
haplotype, whereby prevalences were greater than 
frequencies in 2000 isolates but a reciprocal relationship 
was observed in the 2006 isolates where frequencies 
were greater than prevalences (Figure 5). 
 
 
DISCUSSION 
 
This study has quantified the difference between 
prevalence and frequency when reporting field data on 
antimalarial drug resistance obtained by direct counting 
of SNPs or haplotypes. Until recently, frequency method 
is  still  a common  reporting method (Pearce et al., 2003, 
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Figure 5. Comparison of the prevalence and frequency of double dhps mutant parasites in the two districts, Rufiji and KU. A = 
prevalence, B = frequency. 
 
 
 
2009; Roper et al., 2003; Malisa et al., 2010, 2011).  
We found greater frequencies than prevalences for the 
sensitive haplotypes and resistant haplotypes conferring 
high resistance to pyrimethamine (CIRN) and sulfadoxine 
(SGEAA), but greater prevalences than frequencies in 
haplotypes conferring mild resistance to pyrimethamine 
(CNCN, CNRN, and CICN) and to sulfadoxine (AAKAA) 
in 2000 and 2006 isolates from the two study sites. This 
finding is consistent with others (Hastings and Smith, 
2008) who assert that frequency reporting method has a 
weakness of underestimation of SNPs/haplotypes 
present at low frequencies. Taken together, the findings 
of this study revealed that in reporting field data by direct 
counting method, frequency underestimates haplotypes 
present at low levels while also amplifying haplotypes 
present at high levels; prevalence on the other hand 
behaved in a vice versa manner.  
The two reporting methods may have relevance in 
different contexts in high malaria transmission setting; if 
the intention is to monitor progression of resistance to 
guide policy makers in a form of early warning signal of a 
deteriorating drug treatment, it is important to use 
frequency to avoid underestimation of the highly resistant 
haplotypes/SNPs. When the aim is to determine parasite 
clearance, information about all forms of the parasite 
becomes useful and hence prevalence may be more 
informative. It is difficult to explain why the frequencies of 
the highly resistant SNPs/haplotypes were greater than 
their prevalences but we speculated that, for the 
successful spread of a resistance, the mutants must be 
transmitted at a faster rate than the sensitive forms. This 
occurs in the presence of drug because of the differential 
survival and reproduction rates conferred by these alleles 
(Anderson et al., 1989).  
The highly resistant mutant parasites survive treatment 
while sensitive and mildly resistant genotypes do not. In 
addition  to  that,  the drug treatment itself, by purging the 
co-infecting sensitive genotypes, promotes assortative 
mating among resistant survivors of treatment. 
Consequently, by virtue of their higher fitness the 
proportion of the unmixed highly resistant 
SNPs/haplotypes by far outweighs the mixed form and 
mildly resistant SNPs/haplotypes, taken together. In our 
previous reports (Malisa et al., 2010), we found that the 
reproduction rates of the mildly resistant dhfr and dhps 
haplotypes were very slow even at a peak SP drug 
pressure keeping an almost constant frequency.  
Observation of higher SGEAA prevalences than 
frequencies in year 2000 was an exception of the 
previous description and requires some explanation. To 
better understand this, one need to first understand the 
malaria treatment policy in Tanzania. Treatment of 
malaria in Tanzania is typically guided by official 
recommendations from the Ministry of Health and Social 
Welfare (MOHSW) regarding drugs of choice for various 
situations. “First-line” treatment refers to the drug officially 
recommended as the drug of first choice for the treatment 
of uncomplicated malaria. “Second-line” treatment refers 
to the drug officially recommended as an alternative 
primarily to be used for treatment of patients in whom the 
first-line treatment failed to clear the infection and other 
select patients (such as those who are hypersensitive to 
the first-line treatment). “Third-line” treatment typically 
refers to the drug recommended for severely ill patients 
(a rescue drug).   
In practice, few treatment failures are recognized and 
patients are often moved directly from first to third-line 
treatment, consequently, little second-line drug is used 
compared to the first-line drug.  At the time of sample 
collection in 2000, Sulfadoxine/pryrimethamine (SP) was 
still a second line treatment and it only replaced 
chloroquine (CQ) as the recommended first-line 
antimalarial treatment on the Tanzanian mainland in 
August  2001,  after  18 years  of  its use as a second-line  
  
 
 
 
treatment since 1983. Clearly, the SP drug selection 
pressure was very low and a result of monitoring of 
resistant dhfr and dhps allelic haplotypes in the same 
area found that the frequency of the most resistant allele, 
the double dhps-triple dhfr (SGAA-CIRN) mutant 
genotype, increased by only 1% during 17 years of SP 
second line use, but there was a dramatic increase by a 
45% during five (2001 to 2006) years of SP first line use 
(Malisa et al., 2011). Consequently, as a result of low 
selection the proportion of mildly resistant alleles also 
remained low leading to the observed higher prevalences 
than frequencies.  
It was important to determine the malaria transmission 
intensity in the two study districts, Rufiji and KU, as the 
complication associated with genotyping of human blood 
infected with malaria parasite occurs in moderate to high 
malaria transmission areas. This is because infections in 
these areas tend to be composed of multiple genetically 
distinct parasite lines (Babiker et al., 1999) and this may 
occur in two ways; through super infection of a host 
following receiving multiple infective bites or through the 
bites of a mosquito carrying a mixture of genotypes within 
its saliva inoculum.  
Analysis of three selectively neutral microsatellites 
markers (Poly A, Pfpk2 and TA109) confirmed high 
malaria transmission in both study districts, in 2000 and 
2006 surveys with MOI ranging from 1 to 9 in both 
populations. Moreover, the study found a remarkably 
similar distribution of MOI in Rufiji and KU districts 
suggesting existence of homogenizing gene flow 
between the two populations. Furthermore, comparison 
between 2000 and 2006 MOI distribution revealed a trend 
toward decreasing malaria transmission which was more 
marked in KU than Rufiji. In 2000, the most common MOI 
was 3 in both populations yet by 2006, the most common 
MOI in Rufiji was 2 and KU was 1.  
In recent years, several studies have reported a 
decrease in malaria transmission (Killeen et al., 2007; 
Okiro et al., 2007) attributing the reduction to the effect of 
transmission blocking interventions such as integrated 
vector control and use of ITNs. 
In conclusion, as researchers continue to report data 
on molecular genotyping of antimalarial drug resistance 
through direct counting of haplotype/SNP, information on 
the implication of reporting the data either in frequency or 
prevalence is important. Our findings have provided 
insight on that area while also confirming previous 
findings (Hasings et al., 2010) which asserts that both 
prevalence and frequency are therefore essential, as 
each may have relevance in different contexts in high 
malaria transmission settings.  
Frequency is essential to gauge the impact of 
intervention on antimalarial drug resistance while 
prevalence may be more relevant when the aim is to 
determine parasite clearance. Researchers are also 
urged to measure haplotypes rather than SNPs because 
the  latter  rarely  act independently and their combination  
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in haplotypes often determines the resistance properties 
of a given parasite. 
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